A-Alpha Bio Partners with Novo Nordisk to Advance AI-Driven Protein Engineering

We are happy to announce a new collaboration with global healthcare leader Novo Nordisk.

The partnership will help accelerate Novo Nordisk’s discovery and design of protein-based therapeutics by training proprietary AI models with high-throughput experimental data generated by A-Alpha’s AlphaSeq platform.

Together with Novo Nordisk, we will apply custom AlphaSeq-generated datasets to train, fine-tune, and benchmark AI models that predict binding affinities for de novo design and optimization across multiple therapeutic scaffolds. These models will support the rapid discovery and development of therapeutics with enhanced affinity, specificity, and developability.

In addition to affinity modeling, we will apply AlphaSeq data to validate a structural protein interaction database, with the goal of improving protein complex prediction and advancing de novo protein design.

AlphaSeq is a high-throughput synthetic biology platform that reimagines yeast surface display to quantitatively measure millions of protein-protein binding affinities simultaneously—such as mapping the complete interaction landscape between libraries of antibodies and antigens.

“This collaboration with Novo Nordisk underscores the unique value of our AlphaSeq platform for training, fine-tuning, benchmarking, and validating AI models to engineer protein therapeutics,” said David Younger, PhD, Co-Founder and CEO of A-Alpha Bio. “We are excited to work together to unlock the transformative potential of AI in drug discovery.”